We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
DaVita (DVA) Beats Earnings and Revenue Estimates in Q2
Read MoreHide Full Article
DaVita Inc (DVA - Free Report) reported second-quarter 2017 adjusted operating earnings of $1.05 per share, beating the Zacks Consensus Estimate of 97 cents. The figure improved 14.1% on a year-over-year basis.
Total revenues declined 25.5% year over year to $2.89 billion, but beat the Zacks Consensus Estimate of $2.88 billion.
DaVita carries a Zacks Rank #3 (Hold).
Business Details
Net dialysis and related lab patient service revenues in the second quarter were $2.67 billion, up 11.9% year over year. Other revenues were $218 million, down 30.7% on a year-over-year basis.
DaVita witnessed impressive results in the Kidney Care business. Net consolidated revenues in the segment were $2.87 billion, up 7% year over year. Adjusted Kidney Care operating income was $438 million, up 12% year over year. As an operating division of the company, DaVita Kidney Care focuses on setting worldwide standards for clinical, social and operational practices in kidney care.
Adjusted U.S. dialysis and related lab services revenues came in at $2.60 billion, up 11.3% year over year. Operating income in the segment inched down 0.2% to $449 million. U.S. dialysis treatments in the quarter under review were 7,331,590, or 93,995 treatments per day. This represents an increase of 4.2% year over year.
For investors’ notice, the company is on track to divest the major segment — DaVita Medical Group (DMG) — to Optum, a subsidiary of UnitedHealth Group Inc. This transaction is subject to regulatory approvals and other customary closing conditions. The results of DMG business’ operations have been reported as discontinued.
During the second quarter, DaVita repurchased a total of 7.8 million shares for approximately $512 million, at an average price of $65.60 per share.
Through Jul 31, 2018, DaVita has repurchased 15.9 million shares for $1.1 billion on a year-to-date basis.
Guidance
DaVita reiterated guidance for 2018.
The company projects Kidney Care consolidated operating income in the range of $1.5-$1.6 billion. Operating cash flow from continuing operations is estimated in the range of $1.4-$1.6 billion. This guidance implies lower expected operating income in the second half of 2018 compared with the first half.
However, effective tax rate is expected in the range of 28.5-29.5%, up from the previous guidance of 26.5-27.5%.
In Conclusion
DaVita ended the second quarter of 2018 on a favorable note, beating the Zacks Consensus Estimate for both the counts. The company witnessed impressive results from the Kidney Care business. As an operating division of the company, DaVita Kidney Care focuses clinical, social and operational practices worldwide. The company’s efforts to control expenses hold promise. A compelling inorganic growth story is another positive.
On the flip side, sluggishness in the Other business is a major headwind for DaVita. The company is facing the adverse effects of pricing pressure in the U.S. medical industry and rise in Medicare insurance costs. The company’s major segment — DaVita Medical Group — has been on track for the divestment to Optum, a subsidiary of UnitedHealth Group Inc. Further, DaVita’s GranuFlo and DaVita Rx units are grappling with multiple issues. These might have a negative impact on the company’s customer base.
Q2 Earnings of MedTech Majors at a Glance
A few better-ranked stocks in the broader medical space, which reported solid earnings this season are Stryker Corporation (SYK - Free Report) , Intuitive Surgical, Inc (ISRG - Free Report) and Illumina, Inc (ILMN - Free Report) .
Intuitive Surgical reported adjusted earnings of $2.76 per share in the second quarter of 2018, which beat the Zacks Consensus Estimate of $2.48. Adjusted earnings improved 38% year over year.
Stryker reported second-quarter 2018 adjusted earnings per share of $1.76, beating the Zacks Consensus Estimate by 1.7%. Earnings improved 15% year over year and also exceeded the high end of the company’s guidance.
Illumina reported adjusted earnings of $1.43 per share, beating the Zacks Consensus Estimate of $1.11.
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +21.9% in 2017, our top stock-picking screens have returned +115.0%, +109.3%, +104.9%, +98.6%, and +67.1%.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - 2017, the composite yearly average gain for these strategies has beaten the market more than 19X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
Image: Bigstock
DaVita (DVA) Beats Earnings and Revenue Estimates in Q2
DaVita Inc (DVA - Free Report) reported second-quarter 2017 adjusted operating earnings of $1.05 per share, beating the Zacks Consensus Estimate of 97 cents. The figure improved 14.1% on a year-over-year basis.
Total revenues declined 25.5% year over year to $2.89 billion, but beat the Zacks Consensus Estimate of $2.88 billion.
DaVita carries a Zacks Rank #3 (Hold).
Business Details
Net dialysis and related lab patient service revenues in the second quarter were $2.67 billion, up 11.9% year over year. Other revenues were $218 million, down 30.7% on a year-over-year basis.
DaVita witnessed impressive results in the Kidney Care business. Net consolidated revenues in the segment were $2.87 billion, up 7% year over year. Adjusted Kidney Care operating income was $438 million, up 12% year over year. As an operating division of the company, DaVita Kidney Care focuses on setting worldwide standards for clinical, social and operational practices in kidney care.
Adjusted U.S. dialysis and related lab services revenues came in at $2.60 billion, up 11.3% year over year. Operating income in the segment inched down 0.2% to $449 million. U.S. dialysis treatments in the quarter under review were 7,331,590, or 93,995 treatments per day. This represents an increase of 4.2% year over year.
For investors’ notice, the company is on track to divest the major segment — DaVita Medical Group (DMG) — to Optum, a subsidiary of UnitedHealth Group Inc. This transaction is subject to regulatory approvals and other customary closing conditions. The results of DMG business’ operations have been reported as discontinued.
DaVita Inc. Price, Consensus and EPS Surprise
DaVita Inc. Price, Consensus and EPS Surprise | DaVita Inc. Quote
Share Repurchase Update
During the second quarter, DaVita repurchased a total of 7.8 million shares for approximately $512 million, at an average price of $65.60 per share.
Through Jul 31, 2018, DaVita has repurchased 15.9 million shares for $1.1 billion on a year-to-date basis.
Guidance
DaVita reiterated guidance for 2018.
The company projects Kidney Care consolidated operating income in the range of $1.5-$1.6 billion. Operating cash flow from continuing operations is estimated in the range of $1.4-$1.6 billion. This guidance implies lower expected operating income in the second half of 2018 compared with the first half.
However, effective tax rate is expected in the range of 28.5-29.5%, up from the previous guidance of 26.5-27.5%.
In Conclusion
DaVita ended the second quarter of 2018 on a favorable note, beating the Zacks Consensus Estimate for both the counts. The company witnessed impressive results from the Kidney Care business. As an operating division of the company, DaVita Kidney Care focuses clinical, social and operational practices worldwide. The company’s efforts to control expenses hold promise. A compelling inorganic growth story is another positive.
On the flip side, sluggishness in the Other business is a major headwind for DaVita. The company is facing the adverse effects of pricing pressure in the U.S. medical industry and rise in Medicare insurance costs. The company’s major segment — DaVita Medical Group — has been on track for the divestment to Optum, a subsidiary of UnitedHealth Group Inc. Further, DaVita’s GranuFlo and DaVita Rx units are grappling with multiple issues. These might have a negative impact on the company’s customer base.
Q2 Earnings of MedTech Majors at a Glance
A few better-ranked stocks in the broader medical space, which reported solid earnings this season are Stryker Corporation (SYK - Free Report) , Intuitive Surgical, Inc (ISRG - Free Report) and Illumina, Inc (ILMN - Free Report) .
While Intuitive Surgical and Illumina sport a Zacks Rank #1 (Strong Buy), Stryker carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Intuitive Surgical reported adjusted earnings of $2.76 per share in the second quarter of 2018, which beat the Zacks Consensus Estimate of $2.48. Adjusted earnings improved 38% year over year.
Stryker reported second-quarter 2018 adjusted earnings per share of $1.76, beating the Zacks Consensus Estimate by 1.7%. Earnings improved 15% year over year and also exceeded the high end of the company’s guidance.
Illumina reported adjusted earnings of $1.43 per share, beating the Zacks Consensus Estimate of $1.11.
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +21.9% in 2017, our top stock-picking screens have returned +115.0%, +109.3%, +104.9%, +98.6%, and +67.1%.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - 2017, the composite yearly average gain for these strategies has beaten the market more than 19X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
See Them Free>>